Pharmascience Inc. has launched Prpms-NITROFURANTOIN (nitrofurantoin monohydrate / macrocrystals capsules) in Canada for the treatment of urinary tract infections.
“With the launch of Prpms-NITROFURANTOIN, manufactured in Canada, we become the first generic bioequivalent to MacroBID on the Canadian market,” said Jean-Guy Goulet, chief operating officer at Pharmascience Inc.
Prpms-NITROFURANTOIN is indicated for the treatment of patients suffering from acute, uncomplicated urinary tract infections, e.g. cystitis, when due to susceptible strains of Escherichia coli and Staphylococcus saprophyticus.1
One in two women will suffer from a urinary tract infection at least once in their lifetime. Most urinary tract infections are caused by bacteria.2
“The launch of this product is a prime example of Pharmascience’s commitment to offering Canadians effective and accessible treatments,” added Mr. Goulet.
References:
1. Prpms-NITROFURANTOIN product monograph. Pharmascience Inc. June 7, 2016.
2. The College of Family Physicians of Canada: Urinary Tract Infections—A common problem for some women.
(Source: Pharmascience Inc.)
Filed Under: Drug Discovery
